Lipidor AB reported positive topline results of its AKP01 Phase III clinical study, using calcipotriol spray against mild to moderate plaque psoriasis. The randomised 277-patient study achieved its primary endpoint demonstrating therapeutic equivalence to comparator measured as reduction of PASI score. Both Lipidors AKP01 and the comparator had a statistically significantly better efficacy compared to the placebo. Lipidor has developed a sprayable calcipotriol product, Calcipotriol/AKVANO 50 µg/g cutaneous solution (AKP01), formulated with the companies patented lipid-based AKVANO® technology which provides more precise dosing and increased patient comfort. The AKP01 Phase III clinical study is a multicenter, randomized, observer-blind and placebo-controlled clinical study with 277 patients treated at 14 clinics across India. The purpose of the study was to evaluate the efficacy and safety of AKP01. The study compared the therapeutic equivalence of AKP01 against Calcipotriol ointment 50 micrograms/g (Sandoz) and against placebo, in patients with mild to moderate plaque psoriasis. The study design consisted of 8 weeks treatment, applied twice daily, 3 mg/cm[2] dosing, males and non-pregnant females, three arms with 119 patients in the AKP01 group, 119 patients in the Calcipotriol ointment group and 39 in the placebo group. Baseline inclusion criteria were mild to moderate plaque type of psoriasis, stable for six months, with Psoriasis Area and Severity Index (PASI) greater than 5, involving 5-10% of body surface area on arms, legs and trunk. Assessments were made at baseline, week 2, 4 and 8. PASI is a well-established scale (0-72) that gives an overall assessment of the severity of the psoriasis symptoms by combining scores for redness, plaque thickness and scaling of the lesions, taking into account the body surface area affected. The primary endpoint was percentage change in PASI from baseline to the end of completed treatment. Therapeutic equivalence to comparator was measured by comparing the 95 % confidence interval with the equivalence interval of -10, 10%.